Cargando…
Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review
Dabigatran, rivaroxaban, apixaban, edoxaban, and betrixaban are direct oral anticoagulants (DOACs). Their inter-individual variability in pharmacodynamics and pharmacokinetics (transport and metabolism) is high, and could result from genetic polymorphisms. As recommended by the French Network of Pha...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826504/ https://www.ncbi.nlm.nih.gov/pubmed/33440670 http://dx.doi.org/10.3390/jpm11010037 |
_version_ | 1783640536024875008 |
---|---|
author | Raymond, Johanna Imbert, Laurent Cousin, Thibault Duflot, Thomas Varin, Rémi Wils, Julien Lamoureux, Fabien |
author_facet | Raymond, Johanna Imbert, Laurent Cousin, Thibault Duflot, Thomas Varin, Rémi Wils, Julien Lamoureux, Fabien |
author_sort | Raymond, Johanna |
collection | PubMed |
description | Dabigatran, rivaroxaban, apixaban, edoxaban, and betrixaban are direct oral anticoagulants (DOACs). Their inter-individual variability in pharmacodynamics and pharmacokinetics (transport and metabolism) is high, and could result from genetic polymorphisms. As recommended by the French Network of Pharmacogenetics (RNPGx), the management of some treatments in cardiovascular diseases (as antiplatelet agents, oral vitamin K antagonists, and statins) can rely on genetic testing in order to improve healthcare by reducing therapeutic resistance or toxicity. This paper is a review of association studies between single nucleotide polymorphisms (SNPs) and systemic exposure variation of DOACs. Most of the results presented here have a lot to do with some SNPs of CES1 (rs2244613, rs8192935, and rs71647871) and ABCB1 (rs1128503, rs2032582, rs1045642, and rs4148738) genes, and dabigatran, rivaroxaban, and apixaban. Regarding edoxaban and betrixaban, as well as SNPs in the CYP3A4 and CYP3A5 genes, literature is scarce, and further studies are needed. |
format | Online Article Text |
id | pubmed-7826504 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-78265042021-01-25 Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review Raymond, Johanna Imbert, Laurent Cousin, Thibault Duflot, Thomas Varin, Rémi Wils, Julien Lamoureux, Fabien J Pers Med Review Dabigatran, rivaroxaban, apixaban, edoxaban, and betrixaban are direct oral anticoagulants (DOACs). Their inter-individual variability in pharmacodynamics and pharmacokinetics (transport and metabolism) is high, and could result from genetic polymorphisms. As recommended by the French Network of Pharmacogenetics (RNPGx), the management of some treatments in cardiovascular diseases (as antiplatelet agents, oral vitamin K antagonists, and statins) can rely on genetic testing in order to improve healthcare by reducing therapeutic resistance or toxicity. This paper is a review of association studies between single nucleotide polymorphisms (SNPs) and systemic exposure variation of DOACs. Most of the results presented here have a lot to do with some SNPs of CES1 (rs2244613, rs8192935, and rs71647871) and ABCB1 (rs1128503, rs2032582, rs1045642, and rs4148738) genes, and dabigatran, rivaroxaban, and apixaban. Regarding edoxaban and betrixaban, as well as SNPs in the CYP3A4 and CYP3A5 genes, literature is scarce, and further studies are needed. MDPI 2021-01-11 /pmc/articles/PMC7826504/ /pubmed/33440670 http://dx.doi.org/10.3390/jpm11010037 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Raymond, Johanna Imbert, Laurent Cousin, Thibault Duflot, Thomas Varin, Rémi Wils, Julien Lamoureux, Fabien Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review |
title | Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review |
title_full | Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review |
title_fullStr | Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review |
title_full_unstemmed | Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review |
title_short | Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review |
title_sort | pharmacogenetics of direct oral anticoagulants: a systematic review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826504/ https://www.ncbi.nlm.nih.gov/pubmed/33440670 http://dx.doi.org/10.3390/jpm11010037 |
work_keys_str_mv | AT raymondjohanna pharmacogeneticsofdirectoralanticoagulantsasystematicreview AT imbertlaurent pharmacogeneticsofdirectoralanticoagulantsasystematicreview AT cousinthibault pharmacogeneticsofdirectoralanticoagulantsasystematicreview AT duflotthomas pharmacogeneticsofdirectoralanticoagulantsasystematicreview AT varinremi pharmacogeneticsofdirectoralanticoagulantsasystematicreview AT wilsjulien pharmacogeneticsofdirectoralanticoagulantsasystematicreview AT lamoureuxfabien pharmacogeneticsofdirectoralanticoagulantsasystematicreview |